NCT00071539View on ClinicalTrials.gov

Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

January 31, 2006

Study Completion Date

July 31, 2006

Conditions
Recurrent Glioblastoma Multiforme
Interventions
DRUG

TP-38

Recombinant chimeric protein

DRUG

TP38

recombinant chimeric protein

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00071539 - Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | Biotech Hunter | Biotech Hunter